The present invention relates to the use of a composition comprising a fixed combination of a) formoterol a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and b) beclometasone dipropionate; for the manufacture of a medicament for use in the prevention and/or treatment of an exacerbation of asthma intermittent asthma and/or episodes in chronic asthma during the maintenance therapy of asthma with the same composition for symptomatic relief when needed.

The present invention relates to the use of a composition comprising a fixed combination of a) formoterol a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and b) beclometasone dipropionate; for the manufacture of a medicament for use in the prevention and/or treatment of an exacerbation of asthma intermittent asthma and/or episodes in chronic asthma during the maintenance therapy of asthma with the same composition for symptomatic relief when needed.

Pharmaceutical formulations comprising beclometasone dipropionate and a salt of formoterol exhibit improved stability and are useful in pressurized metered dose inhalers (pMDIs).

Formulation in the form of aqueous suspension of drug particles of a corticosteroid for topical administration are effective for the prophylaxis and/or treatment of a dermatological disease such as atopic dermatitis, acne and psoriasis.

Provided is the use of a) formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt

The invention concerns an aerosol formulation suitable for administering to COPD patients by means of a pressurized metered dose inhaler (pMDI), comprising glycopyrronium bromide in combination with formoterol. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation further comprises beclometasone dipropionate.